SHRX.V Sharp Therapeutics Corp.

Healthcare Biotechnology TSX Venture Exchange
1.37 CAD
Close of Nov 7, 2026
0.9100 4.75
Market cap
CAD 43.3M
P/E
-
P/B
6.04x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is SHRX.V undervalued?

Graham number

The Graham number of Sharp Therapeutics Corp. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sharp Therapeutics Corp. fundamental analysis

No fundamental analysis for Sharp Therapeutics Corp. yet.

Sharp Therapeutics Corp. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sharp Therapeutics Corp.

Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive assays mimicking the genetic disease state, enabling discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a custom-built, cloud-distributed analytics platform t…

Full company profile